Intrinsic Fibrillation of Fast-Acting Insulin Analogs
Open Access
- 1 March 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 6 (2), 265-276
- https://doi.org/10.1177/193229681200600209
Abstract
Aggregation of insulin into insoluble fibrils (fibrillation) may lead to complications for diabetes patients such as reduced insulin potency, occlusion of insulin delivery devices, or potentially increased immunological potential. Even after extensive investigation of fibril formation in regular human insulin, there are little published data about the intrinsic fibrillation of fast-acting analogs. This article investigates and compares the intrinsic fibrillation of three fast-acting insulin analogs—lispro, aspart, and glulisine—as a function of their primary protein structure and exclusive of the stabilizing excipients that are added to their respective commercial formulations. The insulin analogs underwent a buffer exchange into phosphate-buffered saline to remove formulation excipients and then were heated and agitated to characterize intrinsic fibrillation potentials devoid of excipient stabilizing effects. Different analytical methods were used to determine the amount of intrinsic fibrillation for the analogs. After initial lag times, intrinsic fibrillation was detected by an amyloid-specific stain. Precipitation of insulin was confirmed by ultraviolet analysis of soluble insulin and gravimetric measurement of insoluble insulin. Electron microscopy showed dense fibrous material, with individual fibrils that are shorter than typical insulin fibrils. Higher resolution kinetic analyses were carried out in 96-well plates to provide more accurate measures of lag times and fibril growth rates. All three analogs exhibited longer lag times and slower intrinsic fibrillation rates than human insulin, with glulisine and lispro rates slower than aspart. This is the first study comparing the intrinsic fibrillation of fast-acting insulin analogs without the stabilizing excipients found in their commercial formulations. Data show different intrinsic fibrillation potentials based on primary molecular structures when the formulation excipients that are critical for stability are absent. Understanding intrinsic fibrillation potential is critical for evaluating insulin analog stability and device compatibility.Keywords
This publication has 64 references indexed in Scilit:
- Macrocyclic β-Sheet Peptides That Inhibit the Aggregation of a Tau-Protein-Derived HexapeptideJournal of the American Chemical Society, 2011
- Molecular basis for insulin fibril assemblyProceedings of the National Academy of Sciences, 2009
- Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrilsProceedings of the National Academy of Sciences, 2008
- Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assemblyProceedings of the National Academy of Sciences, 2008
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Kinetics of Insulin Aggregation: Disentanglement of Amyloid Fibrillation from Large-Size Cluster FormationBiophysical Journal, 2006
- Structure of the cross-β spine of amyloid-like fibrilsNature, 2005
- Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid FibrilsScience, 2005
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004
- Rationalization of the effects of mutations on peptide andprotein aggregation ratesNature, 2003